Ishares Nasdaq Biotechnology Index Fund ETF News

HCR Wealth Advisors raised its holdings in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 0.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,236 shares of the financial services providers stock after buying an additional 181 shares during the period. []

Bridge Advisory LLC grew its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 9.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,311 shares of the financial services providers stock after purchasing an additional 276 shares during []

Folger Nolan Fleming Douglas Capital Management Inc. raised its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 3.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,541 shares of the financial services providers stock after acquiring an additional 1,898 shares during the []

Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.

Janney Montgomery Scott LLC reduced its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,998 shares of the financial services providers stock after selling 3,138 shares during the []

Jaffetilchin Investment Partners LLC lowered its holdings in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 35.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,503 shares of the financial services provider’s stock after selling 21,868 shares during the quarter. Jaffetilchin Investment Partners […]

Ferguson Wellman Capital Management Inc. trimmed its holdings in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 13,043 shares of the financial services providers stock after selling 260 shares during the period. Ferguson Wellman Capital Management Inc.s holdings in iShares Nasdaq Biotechnology ETF were []

Ferguson Wellman Capital Management Inc. trimmed its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.0% during the third quarter, Holdings Channel reports. The firm owned 13,043 shares of the financial services providers stock after selling 260 shares during the quarter. Ferguson Wellman Capital Management Inc.s holdings in iShares Nasdaq Biotechnology ETF were worth $2,109,000 []

Kestra Private Wealth Services LLC grew its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 15.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,927 shares of the financial services providers stock after acquiring an additional 920 shares during the quarter. Kestra Private []

Accurate Wealth Management LLC acquired a new stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 29,999 shares of the financial services providers stock, valued at approximately $5,009,000. iShares Nasdaq Biotechnology ETF makes up about 4.4% of []

Fifth Third Securities Inc. acquired a new position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,864 shares of the financial services providers stock, valued at approximately $463,000. Other hedge funds and other institutional investors have []

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more re

Take a look at some top-ranked ETFs that might help strengthen your portfolio and rake in some good returns.

Greg Zuckerman, special writer at the Wall Street Journal, joins the 'Halftime Report' to discuss why Moderna and Pfizer's underperformance in the markets are causing hedge funds to lose money.

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms.